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HMBA-induced differentiationSphingosine kinase 1 (SPHK1) overexpression in malignant cells has been reported. Mouse Friend cells
showed higher SPHK1 but not SPHK2 expression compared with other mouse cell lines. A Sphk1 promoter
analysis demonstrated the region between−53 bp and the ﬁrst exon as the minimal promoter. Further pro-
moter truncation revealed the importance of a MYB-binding site. EMSA using this region as the probe demon-
strated one band containing c-MYB protein, and its intensity decreased during erythroid differentiation with
hexamethylane bisacetamide (HMBA), a potent inducer of erythroid differentiation of Friend cells. ChIP assay
also revealed in vivo binding of c-MYB. c-MYB overexpression and siRNA for c-Myb affected SPHK1 expression,
conﬁrming the important regulatory role of c-MYB in SPHK1 expression. HMBA reduced c-MYB expression
rapidly. Induced differentiation by HMBA caused a marked and rapid reduction of SPHK1 mRNA, protein
and enzyme activity leading to the rapid decrease of cellular sphingosine 1-phosphate level. Moreover, termi-
nally differentiated cells did not resume SPHK1 expression. Compared with original Friend cells, stable
overexpression of wild-type SPHK1 showed higher cell proliferation, resistance to cell death by serum deple-
tion. Interestingly, HMBA-induced differentiation of these cells was delayed but not completely suppressed. In
contrast, SPHK inhibitor and its siRNA inhibited cell growth and enhanced HMBA-induced differentiation sig-
niﬁcantly, suggesting that SPHK1 delayed HMBA-induced differentiation by its cell proliferation-promoting
activity. Effects of pertussis toxin, a G-protein-coupled receptor inhibitor, and S1P receptor antagonist on Friend
cell growth and differentiationwere negligible, suggesting the importance of the intracellular SPHK1/S1P signal-
ing in Friend cells.
© 2013 Elsevier B.V. All rights reserved.1. Introduction
Sphingolipids (SPLs) are complex lipids containing an amide-linked
fatty acid and a long-chain amino alcohol, sphingoid base. Recently,
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l rights reserved.and ceramide 1-phosphate have been considered as intra- or inter-
cellular signaling molecules in numerous biological processes [1].
Spiegel and colleagues proposed a sphingolipid rheostat model, where
the balance between ceramide and S1P determines the cell's fate [2,3].
Ceramide acts as a signaling molecule, leading to cell responses such
as apoptosis, growth arrest, cell differentiation and inﬂammation,
whereas S1P mostly works as an inhibitor of apoptosis and as a stimu-
lator of cell proliferation.
S1P is produced by sphingosine kinases (SPHK) 1 and 2. Discovery of
S1P receptors in cell membrane helped elucidate the signaling pathway
downstream of S1P/S1P receptors [4,5]. SPHK1 expression stimulates
proliferation and protects against apoptosis, and its overexpression is
oncogenic in NIH3T3 cells [6]. On the contrary, overexpression of
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play an important role in cancer growth and survival [8]. Previous re-
ports including ours have shown increased SPHK1 expression in various
cancer and leukemia cells [9–13]. Considering the role of sphingolipid
metabolic enzymes as a chemotherapy sensor [10,14], the elucidation
and regulation of SPHK1 expression is clinically important.
The mouse erythroleukemia cell line caused by the Friend virus
(Friend cells) has been extensively studied because of its suitability
as a virus oncogenesis model [15,16] and also because of its prominent
differentiation toward erythroid lineage by chemical inducers such
as DMSO or hexamethylene bisacetamide (HMBA) [17]. With HMBA
treatment, almost all Friend cells gradually ceased to proliferate and
exhibited erythroid phenotypes such as high cellular hemoglobin
within 4 or 5 days, although the rate of erythroid differentiation varies
among sublines.
A Friend virus complex contains a replication-defective spleen
focus-forming virus (SFFV) and a replication-competent Friend mu-
rine leukemia virus (F-MuLV). gp55, a product of the SFFV env gene,
interacts with the erythropoietin receptor and constitutively acti-
vates its downstream signaling pathways, allowing proliferation of
virus infected cells in the absence of erythropoietin [18]. The Friend
virus is usually found upstream of the PU.1 gene (Sfpi1), leading to
overexpression of the wild-type transcription factor, PU.1 [18,19].
Similar to Friend cells, Spi-1/PU.1 transgenic mice develop multistep
erythroleukemia [20]. Le Scolan et al. have reported that overex-
pression of SPHK1 is an oncogenic event in mouse erythroleukemia
cell lines developed from PU.1-transgenic mouse [21].
The sequential changes of proto-oncogenes (c-Myb, Fli-1, and
Sfpi1) and cell cycle regulators (CDK2, 4 and 6) during the chemically
induced differentiation process have been reported [22–25]. Thus,
Friend cells have been utilized as an excellent model of leukemia
differentiation therapy. However, it remains to be determined how
SPHK1 overexpression is induced in Friend cells, how SPHK1 is regu-
lated during this differentiation process, and whether SPHK level af-
fects HMBA-induced differentiation. We approached these issues by
(1) the analysis of SPHK1 transcriptional mechanism in Friend cells;
(2) the analysis of the stably SPHK1- and SPHK2-overexpressing
Friend cells; and (3) experiments using a chemical SPHK inhibitor,
siRNA for Sphk1, and S1P receptor antagonists.
The present analysis indicated (1) c-MYB is themajor transcription
factor of the SPHK1 of Friend cells, (2) SPHK1 is rapidly decreased dur-
ing HMBA-induced differentiation through reduced c-MYB expres-
sion, and (3) SPHK1 expression level affects the HMBA-induced
differentiation of Friend cells. The pathophysiological signiﬁcance of
these ﬁndings was discussed.2. Materials and methods
2.1. Vectors and reagents
Wild-type (WT) expression vectors of mouse SPHK1 [21] and
SPHK2 (as FLAG-tagged form) [26] were generous gifts of Dr. F.
Moreau-Gachelin (Inserm U528, Institut Curie, Paris, France) and
Dr. T. Yoshimoto (Tokyo Medical University, Tokyo, Japan), respec-
tively. WT- -Sphk1 cDNA inserts were obtained by PCR ampliﬁcation
and reinserted into a MSCV-IRES-GFP vector, which was derived
from Dr. A. Katsumi (Hamamatsu University School of Medicine,
Hamamatsu, Japan). The c-MYB expression vector and GST-c-MYB
expression vector [27] were the gifts of Dr. A. Tomita (Nagoya Uni-
versity Graduate School of Medicine, Nagoya, Japan). c-Myb cDNA
was reinserted in pcDNA3.1 (Invitrogen, Carlsbad, CA, USA) and was
used for transfection. HMBA was purchased from Sigma (St. Louis,
MO, USA). Sphingosine kinase inhibitor was obtained from Calbiochem
(San Diego, CA). Pertussis toxin, VPC23019, and CAY10444 were from
Biomol (Plymouth Meeting, PA, USA).2.2. Cell lines
Original Friend cells were described previously [28,29]. Mouse
IL-3 dependent cell lines, BaF/3 and 32D, were maintained in RPMI
1640 medium supplemented with 10% FCS and 3% conditioned me-
dium from WEHI 3B cells (WEHI-CM) as the source of IL-3. A mouse
myoblastoid cell line, C2C12, and a mouse ﬁbroblastic cell line,
NIH3T3, were cultured in DMEM medium containing 5% FCS.
2.3. Establishment of stable transfectants
Stable transfectants of SPHK1 were established by sorting GFP-
positive cells with the ﬂow cytometer after retrovirus vector transfec-
tion. After sorting, suitable clones after a single cell culture were
selected with Western blotting using our anti-SPHK1 antibody. This
anti-mouse SPHK1 antibody was prepared by immunizing rabbit
with the C-terminal peptide of mouse SPHK1 we described earlier
[30]. It was previously used in other mouse erythroleukemia cell
lines [21]. Stable SPHK2 transfectants were also established after
G418 selection. After limiting dilution, suitable clones were selected
byWestern blotting using anti-FLAG antibody (Santa Cruz Biotechnol-
ogy Inc., Santa Cruz, CA, USA), and then SPHK2 expression was also
conﬁrmed using anti-SPHK2 antibody (Santa Cruz) as shown in Sup-
plementary Fig. 5a. To establish c-MYB-transfectants, Friend cells
were transfected with the c-MYB expression vector, and selected
with G418. Suitable clones were chosen with Western blotting using
anti-c-MYB antibody (Santa Cruz).
2.4. Hemoglobin staining, viable cell counting and commitment assay
Hemoglobin-positive cells were counted manually with liquid ben-
zidine staining [28]. A commitment assay to detect the percentage of
committed cells to terminal erythroid differentiation was performed
in triplicate as described previously [28]. The percentagewas calculated
as the mean±SD. Viable cells were counted in triplicate using trypan-
blue dye exclusion method.
2.5. Quantitative RT-PCR
QRT-PCRwas performed according to the method described previ-
ously [31] Primer sequences were as follows: mSPHK1; forward 5′-GG
AGGAGGCAGAGATAAC-3′, reverse 5′-TTAGCCCATTCACCACTTCA-3′,
mSPHK2; forward 5′-GTGCCCTCACGTGTCTCCT-3′, reverse 5′-GCATG
GTTCTGTCGTTCTGTC-3′, and mouse α1-globin; forward 5′-GAGCT
GAAGCCCTGGAAAGGATG-3′, reverse 5′-GACCTTCTTGCCGTGACCCT
TG-3′, mouse β1-globin; forward 5′-CAACTTCAGAAACAGACATCAT
GG-′3, reverse 5′-TAGACAACCAGCCTGCC-′3, β-actin; forward 5′-CCG
TGAAAAGATGACCCAGA-3′, reverse 5′-GTCTCCGGAGTCCATCACAA-3′.
PCR conditions were 30 s initial denaturation followed by 40 cycles
of 96 °C for 5 s, and 60 °C for 31 s. A dissociation proﬁle was generated
for each run to verify speciﬁcity of the ampliﬁcation. The PCR condi-
tion for β-actin was the same as that of SPHK except that the applied
volume was 10 times lower than that of SPHK1. The relative expres-
sion of the SPHK and globin message was evaluated by calculating
the ratio of SPHK or globin/β-actin.
2.6. SPHK enzyme activity
SPHK1 and SPHK2 enzyme activities were measured separately as
described before [32]. Brieﬂy, SPHK1 activity was determined either
in the presence of 0.25% Triton X-100 (SPHK1) or in 1 M KCl (SPHK2).
SPHK1 activity was examined in the presence of 50 μM sphingosine
and [γ-32P] ATP (10 μCi, 1 mM) containing 10 mMMgCl2 in 0.25% Tri-
ton X-100, which inhibits SPHK2. SPHK2 activity was determined with
sphingosine added as a complex with 4 mg/ml bovine serum albumin
and [γ-32P] ATP containing 10 mM MgCl2 in the presence of 1 M KCl,
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inhibited. Labeled S1P was extracted and separated by thin layer chro-
matography on silica gel G60 with 1-butanol/acetic acid/H2O (3:1:1)
as the solvent. The spot of S1P on the thin layer chromatography plate
was visualized by autography and quantiﬁed using a densitometer.
2.7. Western blotting
Anti-FLAG, anti-Fli-1, anti-PU.1, anti-c-MYB, anti-GATA-1, anti-GATA-
2, and anti-SPHK2 antibodies were purchased from Santa Cruz. In addi-
tion to our anti-SPHK1 antibody, we used anti-SPHK1 antibody (#3297)
from Cell Signaling Technology (Beverly,MA. USA) in the supplementa-
ry experiments. Anti-β-actin antibody was purchased from Cytoskel-
eton Inc. (Denver, CO, USA). Western blotting was performed using
Immobilon Western Chemiluminescent HRP Substrate (Millipore,
Billerica, MA) as described by Sobue et al. [33].
2.8. Cellular sphingosine 1-phosphate measurement
Cellular sphingosine 1-phosphate (S1P) was measured according
to liquid chromatography followed by tandem mass spectrometry
(LC-MS/MS) as described before with minor modiﬁcations [12].
2.9. RNA ligase-mediated rapid ampliﬁcation of 5′-cDNA ends (5′RACE)
and promoter cloning of mouse Sphk1
Sphk1 transcription start site was determined by 5′RACE method
(Invitrogen) using a primer set shown in Supplementary Table 1.
For promoter cloning, we obtained approximately 1.7 kb of frag-
ment covering the 5′ region of exon 1 of mouse Sphk1. This fragment
was inserted into the BglII and HindIII sites of the pGL3 basic vec-
tor (Promega, Madison, WI, USA) and named −1.7 kb/luc. We uti-
lized the endogenous BglII site located around −1.7 kb from the
ﬁrst exon. Eight deletion mutants (named −322, −265, -241, −234,
−164, −53, −21, and −4 bp/luc) and 4 mutated promoter vectors
(−53 mut1, mut2, mut3, and −21 mut/luc) were constructed with
either restriction enzyme digestion or a PCR-based method. Primer
sets used for PCR ampliﬁcation are shown in Supplementary Table 1.
Vectors of −53 bp/luc or −4 bp/luc were constructed by digestion
with SmaI or StyI, respectively, followed by blunting and self-ligation.
The sequence of truncated or mutated luciferase vectors was con-
ﬁrmed. Promoter analysis was performed using these various lengths
of luciferase vectors. Six microliters of Fugene 6 (Roche, Mannheim,
Germany), 2 μg of luciferase vector, and 1 μg of β-gal expression vector
were incubated for 15 min in serum free medium (total volume of
100 μl) according to the manufacturer's manual. Then, the mixture
was directly added to Friend cells (2.5×105/ml) cultured in serum
containing culture medium. Assay was performed in triplicate. After
24 h, cells were collected and luciferase activity and β-gal activity
were measured as described previously with minor modiﬁcation [33].
2.10. Preparation of c-MYB protein
c-MYB proteinwas puriﬁed by digesting GST-c-MYB fusion protein
by Factor Xa according to the manufacturer's manual (Amersham
Biosciences, Little Chalfont, Buckinghamshire, UK). c-Myb cDNA was
inserted into a pGEX-5X-2 expression vector (Amersham Biosci-
ences). Fusion proteins were collected after stimulating GST-c-MYB
protein production in E. Coli, BL21, by 0.5 mM IPTG. Bacteria were
lysed in modiﬁed NETN buffer (20 mM Tris–HCl (pH 8.0), 100 mM
NaCl, 1 mM EDTA and 1% Triton X), then were sonicated. After centri-
fugation, supernatants were incubated with MagneGST glutathione
particles (MagneGST™ Pull-Down System, Promega) overnight at
4 °C in NETN buffer (20 mM Tris–HCl (pH 8.0), 100 mM NaCl, 1 mM
EDTA and 0.5% NP-40). GST-MYB proteinwas cleaved by bovine Factor
Xa (Funakoshi Co., Tokyo, Japan) and c-MYB was isolated.2.11. Electrophoresis mobility shift assay (EMSA)
Nuclear extract was prepared from original Friend cells with or
without HMBA treatment for 48 hours. EMSA was performed as de-
scribed previously [31]. The labeled probe used was illustrated in
Fig. 2a. A cold competitor was used 10 or 100 times as much as the la-
beled probe. Anti-c-MYB antibody was used at 2 or 6 μg/each sample.
Isolated c-MYB fromGST-c-MYBproteinwas used in someexperiments.
2.12. Chromatin immunoprecipitation (ChIP) assay
ChIP assaywas performed as described previously [34]. Friend cells
were used for cross-linking with formaldehyde. For the immunopre-
cipitation, normal rabbit IgG or anti-c-MYB antibody (500 ng/each
sample) was added to the same amount of nuclear protein and incu-
bated at 4 °C overnight. Immunocomplexes were extracted, and the
cross-linking was reversed by heating elutes at 65 °C overnight. Elutes
were then digested with proteinase K at 50 °C for 2 hours and ex-
tracted with phenol/chloroform/isoamyl alcohol. DNA was puriﬁed
by ethanol. The Sphk1 promoter region was PCR-ampliﬁed by primers
as described in Supplementary Table 1.
2.13. Transient transfection of siRNA
Friend cells were transfected with siRNA using Lipofectamine
RNAiMAX (Invitrogen). siRNAs for cMyb and mouse Sphk1 were pur-
chased from Sigma Genosys (Hokkaido, Japan), and their sequences
were based on the previous report [31,35]. Nonspeciﬁc siRNAwas pur-
chased from QIAGEN (Hilden, Germany).
2.14. Statistical analysis
Statistical signiﬁcances were analyzed using Student's t-test or
one-way factorial analysis of variance and multiple comparison test
(Fisher's method) using Excel software (Microsoft).
3. Results
3.1. SPHK1 and SPHK2 expression of various mouse cell lines
We examined SPHK1 and SPHK2 protein levels of Friend cells as
well as several mouse cell lines (Supplementary Fig. 1a). SPHK1 pro-
tein level of Friend cells was much higher than those of other mouse
cell lines analyzed, whereas SPHK2 protein level was not. This tenden-
cy was also demonstrated in mRNA level by the quantitative RT-PCR.
For example, SPHK1 mRNA level of Friend cells was about six times
higher than that of BaF3 cells, whereas SPHK2 mRNA level of Friend
cells was about a half compared to BaF3 cells (data not shown). In
Western blotting, two molecular sizes of SPHK1, 43 kDa and about
28 kDa were observed in cell lines with higher SPHK1 expression.
A molecule of 43 kDa is consistent with the estimated molecular
weight from mouse Sphk1a cDNA. Actually, Le Scolan et al. [21] re-
ported overexpression of two SPHK1 proteins in the mouse erythro-
leukemia cell lines they established. We reexamined the SPHK1
protein levels using the anti-SPHK1 antibody fromCell Signaling Tech-
nology, which was reported to detect mouse SPHK1. In Supplementa-
ry Fig. 1b(B), these two bands (43 kDa and 28 kDa) as well as many
non-speciﬁc bands were also detected in Friend cells.
siRNA for mouse Sphk1 reduced the intensity of these two bands of
Friend cells (Supplementary Fig. 1c). Moreover, transient transfection
of mouse SPHK1a into NIH3T3 cells produced two protein bands
with 43 and 28 kDa (Supplementary Fig1d). Thus, our results suggest
that this 28 kDa protein was derived from mouse SPHK1a protein.
Concerning the appearance of low molecular weight band, Kihara et
al. [36] reported the presence of small SPHK1, and hypothesized that
the small SPHK1 molecule might be derived from mouse SPHK1b but
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did not reveal the presence of a mouse Sphk1b transcription start
site, and this 28 kDa band was also observed in Friend cells over-
expressing mouse SPHK1a (Fig. 5a).
We then tried to characterize this 28 kDa protein. In Supplementa-
ry Fig. 2a and b, the fractionation pattern of Friend cell lysatewas illus-
trated by the preparatory Superose 6 column (a) and the ﬁnal
Superdex 75 column (b) chromatography connected with SMART
HPLC system (Pharmacia LKB Biotechnology, Uppsala, Sweden).
Three fractions (fraction 19–fraction 21 by Superose 6) were collected
and separated by Superdex 75. Although we could not completely
separate these two proteins under our experimental condition even
using other columns such as monoQ (data not shown), the fraction
22 separated by the Superdex 75 column (b) contained 43 kDa mole-
cule much more than 28 kDa, whereas fraction 25 contained more
28 kDa molecule than 43 kDa. Furthermore, we compared the proﬁle
of SPHK1 enzyme activity of each fraction. Interestingly, the SPHK1
enzyme proﬁle paralleled those of 43 kDa SPHK1 but not those of
28 kDa SPHK1, suggesting that 28 kDa SPHK1 protein had little or no
enzyme activity. The combination of fraction 22 and fraction 25 did
not reduce the total SPHK1 enzyme activity (Supplementary Fig. 2c),
indicating that 28 kDa did not play a dominant negative role.
3.2. 5′-promoter analysis
Based on our 5′ RACE experiments, we determined the transcrip-
tion start point of Sphk1 in Friend cells. Our identiﬁed start site is
78 bp upstream of Sphk1a type based on the database available on
line (NM_025367) (data not shown). We could not observe the
transcription start site of mouse Sphk1b type under our 5′RACE exper-
imental condition. Promoter analysis using various lengths of reporterFig. 1. Promoter analysis of mouse Sphk1 in Friend cells. (a) 5′-promoter of Sphk1 was clon
forms of 5′-promoter reporter vectors were prepared with−1.7 kb/luc as starting material
construct was illustrated at left. (b) Promoter analysis was performed using various reporte
notes c-MYB-binding site. Squares show v-MYB-binding site, whereas circles illustrate Ets-
Promoter assay was performed as described in Materials and methods.vectors revealed that the region between −53 and −4 bp from the
ﬁrst exon is sufﬁcient for the promoter activity of Friend cells
(Fig. 1a). We also examined HMBA-treated Friend cells, but DNA
transfection efﬁciency was too low to obtain reliable results. Thus,
we further analyzed this region by inserting mutations into the puta-
tive transcription factor binding sites as illustrated in Fig. 1b left. It
shows that the proximal MYB-binding site (Area II) was the most im-
portant part within this area, though the other two binding sites
(Areas I and III) also demonstrate some promoter activity. Thus, we fo-
cused on this Area II and c-MYB protein.3.3. EMSA
The promoter region containing three MYB-binding sites and one
Ets-binding site (shown in Fig. 2a containing Areas II and III of Fig. 1b)
was used as the biotin-labeled probe for EMSA. Nuclear extracts of
Friend cells produced three bands, 1, 2 and 3, although bands 1 and
2 were very weak (Fig. 2b). Bands 2 and 3 competed with the same
non-labeled probe, suggesting the speciﬁcity of these band forma-
tions. Anti-c-MYB antibody decreased band 3, although not complete-
ly (Fig. 2c). Therefore, we produced c-MYB protein from GST-c-MYB
fusion protein as described in Materials and methods. It was shown
that band 3 contained c-MYB protein (Fig. 2d). HMBA-treated Friend
cells demonstrated the reduction of band 3, which paralleled the cel-
lular c-MYB protein level (Fig. 4a). Moreover, band 1 increased its in-
tensity in HMBA-treated Friend cells (Fig. 2e). The complex occupancy
of this promoter region by transcription factors except for c-MYB in
HMBA-treated cells suggests that these changes are the possible inhibi-
tion mechanism of Sphk1 transcription by HMBA. Further analysis is
needed to identify suppressive transcription factors involved.ed by PCR method as described in the Materials and methods. Truncated and mutated
s. Promoter analysis was performed as described in Materials and methods. Respective
r vectors with mutation. Three areas (I, II and III) are tentatively named. Diamond de-
binding site. Open symbols represent wild-type and solid ﬁgures denote mutated one.
Fig. 2. EMSA. EMSA was performed with biotin labeled probe containing region II and III. (a) Location of the labeled oligoprobe was illustrated. (b) Cold denotes cold competitor
(10- or 100-fold excess). Each band was named bands 1, 2, or 3. (c) Supershift experiment was performed using anti-c-MYB antibody (2 or 6 μg/each sample). Longer exposure time
was used to detect weak band 1 and 2 clearly. (d) EMSA using nuclear extract and puriﬁed c-MYB protein. EMSA was performed using Friend cell nuclear extract (designated as NP)
or isolated c-MYB protein. Molecular sizes of GST-MYB and c-MYB isolated by Factor Xa digestion are shown in the lower part. (e) Nuclear extracts were prepared from Friend cells
with or without HMBA treatment for 48 h.
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SPHK1 expression
Fig. 3a illustrates the DNA region ampliﬁed in the ChIP assay. In vivo
binding of c-MYBwas clearly shown (Fig. 3b).Moreover, c-Myb silencingFig. 3. ChIP assay and modulation of c-MYB expression level by siRNA for c-Myb or c-MY
performed as described in Materials and methods. (c) siRNA for c-Myb or nonspeciﬁc (c
were collected 72 h after transfection and Western blotting was performed using ant
mock-vector were transfected to Friend cells according to Materials and methods. Western
was different so as to allow detection of the differences between control and suppressed c-
control and c-MYB-overexpressed Friend cells was measured according to Materials and me
inal cells and c-MYB-overexpressed cells.by its siRNA and stable c-MYB overexpression proved that the c-MYB
level signiﬁcantly affected SPHK1 expression (Fig. 3c and d). Increased
cellular S1P level was conﬁrmed in c-MYB-overexpressed Friend cells
(Fig. 3e). We also conﬁrmed c-MYB-induced SPHK1 overexpression in
NIH3T3 cells (Supplementary Fig. 1e).B expression vector. (a) Primers used for ChIP assay were shown. (b) ChIP assay was
ontrol) siRNA was transfected transiently according to Materials and methods. Cells
i-SPHK1, anti-c-MYB, and anti β-actin antibody. (d) c-MYB expression vector and
blotting was performed as shown in Fig. 3c. Exposure time of c-MYB Western blotting
MYB (Fig. 3c) or between mock and overexpressed c-MYB (Fig. 3d). (e) Cellular S1P of
thods. The asterisk means the statistically signiﬁcant difference, pb0.001, between orig-
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differentiation of Friend cells
We next examined HMBA-induced differentiation of the original
Friend cells. The commitment to erythroid differentiation reportedly
precedes the expression of erythroid lineage-speciﬁc gene expres-
sion as well as their protein expression [37]. The increase of the
committed cells preceded the increase of hemoglobin-positive cells
as well as mouse globin mRNAs by about 16–24 h, and the increase
of hemoglobin-positive cells and mouse globin mRNAwas well corre-
lated. (Supplementary Fig. 3a and b). During HMBA treatment, Friend
cells rapidly decreased SPHK1 protein expression, whereas SPHK2
protein did not decrease by HMBA but rather increased slightly
(Fig. 4a). Moreover, removal of HMBA from the culture medium on
day 3 did not restore SPHK1 expression (Fig. 4b), suggesting that
fully committed Friend cells by HMBA did not recover SPHK1 expres-
sion as well as cell proliferation capacity. In contrast, SPHK2 did not
show such signiﬁcant changes with this treatment (data not shown).
Sphk1 mRNA and SPHK1 enzyme activity also rapidly decreased by
HMBA (Fig. 4c and d). Cellular S1P produced by SPHKwas also rapidly
decreased during HMBA-induced differentiation (Fig. 4e), suggesting
the signiﬁcant role of SPHK1 but not SPHK2 in Friend cell differentia-
tion. We could not measure S1P in culture medium, because Friend
cells could not maintain cell viability in serum-depleted or reduced
medium for a long period of time, which is a necessary step to exclude
serum S1P for our S1P measurement by LC/MS/MS.
To prove the effects of proto-oncogenes reported previously con-
cerning Friend cells [22] on SPHK1 expression, we examined FLI-1 and
PU.1 proteins, which are reported to decrease during HMBA-inducedFig. 4. SPHK1 expression during HMBA-induced differentiation of Friend cells. (a) Friend ce
lected sequentially. Antibodies used are described in Materials and methods. (b) Friend cells
cultures were continued for another 3 days. Western blotting of SPHK1 and β-actin was pe
quantitative RT-PCR according to Materials and methods. Open column means control Friend
regarded as 1.0. (d) Friend cells were cultured with 5 mM of HMBA in triplicate. SPHK1 enz
was measured by the LC-MS/MS according to Materials and methods. Friend cells were cult
triplicate. Solid column shows HMBA-treated cells (Day 1 and Day 3), while open column is
cells.differentiation [23]. c-MYB expression was also examined based on
the data shown in Figs. 1, 2, and 3. HMBA rapidly decreased c-MYB,
FLI-1 and PU.1 proteins, whereas GATA-1, which regulates erythroid-
lineage speciﬁc phenotype, was gradually increased by HMBA from
day 1 (Fig. 4a).
3.6. Effects of SPHK1 and SPHK2 overexpression
Because rapid decrease of SPHK1 was observed during HMBA-
induced differentiation, we established SPHK1-overexpressing Friend
cells to examine whether stable overexpression of SPHK1 affects
cell proliferation, survival and differentiation. Fig. 5a shows that
established SPHK1 subclones exhibited high GFP and SPHK1 protein
levels, because we used MSCV-IRES-GFP retrovirus vector, which
expresses GFP and SPHK1, separately and simultaneously. These
subclones possessed high SPHK1 enzyme activity as well as high cellu-
lar S1P levels (Fig. 5b). SPHK1-WT sc2 exhibited higher cell prolifera-
tion than original Friend cells, and showed resistance against serum
depletion-induced cell death (Fig. 5c left and middle). Furthermore,
erythroid differentiation of SPHK1-WTwas delayed but not complete-
ly suppressed compared with the original Friend cells (Fig. 5c right).
Other clones (SPHK1-WT sc3) exhibited similar results (data not
shown). We also examined sequential changes of PU.1, FLI-1, and
c-MYB protein as well as the cellular S1P level of HMBA-treated
SPHK1-overexpressed sc2. PU.1, FLI-1, and c-MYB exhibited the simi-
lar rapid decrease as those observed in original Friend cells (Supple-
mentary Fig. 4a). Interestingly and unexpectedly, the cellular S1P
levels also decreased gradually in spite of stable SPHK1 expression
(Supplementary Fig. 4b), suggesting the possibility that HMBA affectslls were treated with 5 mM of HMBA. Western blotting was performed using cells col-
were cultured with HMBA for 3 days, then HMBA was removed from the medium and
rformed using cells collected sequentially. (c) Sphk1 mRNA level was measured by the
cells. Solid columns show HMBA-treated cells. Sphk1mRNA of control Friend cells was
yme activity was measured according to Materials and methods. (e) Cellular S1P level
ured with 5 mM of HMBA. Cells were collected and their cellular S1P was measured in
control Friend cells. The asterisk denotes pb0.001 between control and HMBA-treated
Fig. 5. Establishment of SPHK1-overexpressing Friend cells. Wild-type (WT) -SPHK1 transfectants were established as described in Materials and methods. (a) Left: Flow cytometry
of cellular GFP was shown. The horizontal axis denotes ﬂuorescence intensity. The vertical axis shows the population. Right: Western blotting of SPHK1 was shown. (b) Left: SPHK1
enzyme activities of original Friend cells and SPHK1-WT were measured according to Materials and methods. Relative activities were calculated with that of original Friend cells as
1.0. Mean±SD was demonstrated. Right: Cellular S1P level of original and SPHK1-overexpresssed sc2 was measured according to Materials and methods. (c) Left and middle parts
illustrate cell growth curve under conventional (10%) or low (0.25%) serum containing culture. The initial cell concentration of the cell growth curve cultured in 10% FCS (left) was
1×104/ml, whereas that of viable cell number analysis (middle) was 5×105/ml. Viable cell numbers were counted with trypan blue dye exclusion. Right: hemoglobin-positive cells
treated 5 mM of HMBA in 10% FCS (+) medium were counted as described in Materials and methods. Cultures were performed in triplicate and the mean±SD was illustrated.
Experiments were repeated at least three times with similar results. Open triangle shows WT-sc2. Solid square means original Friend cells. The asterisk means statistically signif-
icant difference, pb0.001, between original Friend cells and WT-SPHK1-overexpressed sc2.
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examined cell proliferation and differentiation of c-MYB overex-
pressed cell lines. Enhanced cell proliferation and delayed differentia-
tion by HMBA were also observed (Fig. 6).
Because SPHK2 slightly increased during differentiation (Fig. 4a), we
also examined SPHK2-WT (sc3 and 4) transfectants (SupplementaryFig. 6. Characterization of c-MYB-overexpressed Friend cells. Viable cell number of original a
and middle). Cells were cultured in triplicate, and the mean±SD was calculated. Seque
overexpressed cells (open triangle) was illustrated (right). The asterisk shows statistically s
cells.Fig. 5 and data not shown). A moderate increase of SPHK2 activity
was observed, but unexpectedly, cellular S1P level was not signiﬁ-
cantly increased in our stably SPHK2-overexpressed cells. Our strat-
egy of G418 selection might not be suitable for producing higher
SPHK2 expressing cells. Cell proliferation as well as differentia-
tion was delayed in SPHK2-WT sc3. (Supplementary Fig. 5c). Othernd c-MYB-overexpressed cells was counted in culture with 10% FCS or 0.25% of FCS (left
ntial change of HMBA-induced differentiation of original (solid square) and c-MYB-
igniﬁcant difference, pb0.001, between original Friend cells and c-MYB overexpressed
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The delayed differentiation observed in SPHK2-overexpressed cells
remains to be elucidated. Nuclear S1P produced by SPHK2 but not
total cellular S1P might be important for cellular functions induced
with activated SPHK2. However, at the moment, the contribution of
SPHK2 in HMBA-differentiation may well be small compared to the
rapid decrease of SPHK1 and cellular S1P during the differentiation
process (Fig. 4).
3.7. Effects of SPHK inhibitor and S1P receptor antagonists
We analyzed the effects of S1P receptor antagonists (pertussis
toxin, VPC23109 for S1P1/3 and CAY10444 for S1P3) to examine
whether Friend cell proliferation and differentiation were due to the
extracellular or intracellular S1P action (Fig. 7a).We used the effective
concentrations of these inhibitors conﬁrmed in previous experiments
[38]. These reagents did not affect cell growth and HMBA-induced dif-
ferentiation of original Friend cells, suggesting that the involvement of
S1P receptor was less likely and that S1P produced by SPHK1 might
function in an intracellular fashion. Fig. 7b left shows that chemical
SPHK inhibitor inhibited cell growth of SPHK1-overexpressed Friend
cells (sc2) dose-dependently. Interestingly, SPHK inhibitor enhanced
differentiation signiﬁcantly (Fig. 7b right). We also examined the ef-
fect of Sphk1 siRNA. Although Sphk1 siRNA did not suppress overex-
pressed SPHK1 protein completely and stably (Fig. 7c), it was shown
that cell growth on day 3 was inhibited by 35% and that erythroid dif-
ferentiation was mildly but signiﬁcantly enhanced (Fig. 7c middle and
right).
4. Discussion
The mouse Friend cell line exhibits terminal erythroid differentia-
tion rapidly and with high efﬁciency by HMBA or DMSO [37]. Differ-
entiated cells lose their proliferation capacity. Similar differentiation
models analyzed are all-trans retinoic acid-induced human acute
promyelocytic leukemia cell lines such as NB4 or HL60 cells [39].
Chemical differentiation induction of leukemia cells is important be-
cause of its potent activity to eradicate leukemia cells via terminal dif-
ferentiation, leading to the search for therapeutic drugs. Friend virus
infection is thought to shift erythropoietin (EPO)-dependent target
cells to EPO-independent ones after virus infection [40,41]. Moreover,
PKC has been considered the cause of EPO-independent growth of
erythroid cells infected with Friend spleen focus-forming virus [42].
However, the mechanism of HMBA-induced differentiation of Friend
cells remains to be fully elucidated.
Based on the previous report by others [21], we examined the
mechanism of SPHK1 overexpression in Friend cells and the role of
SPHK1 during the erythroid differentiation process. Our results con-
ﬁrmed higher SPHK1 expression of Friend cells than various other
mouse cell lines (Supplementary Fig. 1a). SPHK2 of Friend cells did
not show a similar overexpression as SPHK1, suggesting different
regulation of SPHK1 and SPHK2 expression. Consistent with these re-
sults, we previously reported higher expressions of SPHK1 but not
SPHK2 in the pre-leukemic state, myelodysplastic syndrome, and
acute leukemia and also in a human erythroleukemia cell line, K562
cells [11,12], suggesting a positive relationship between SPHK1 and
leukemogenesis.
We experienced the presence of two molecules of mouse SPHK1
(43 kDa and 28 kDa) in cellswith higher SPHK1 expression, as reported
before by others [21]. Because the smallermoleculewas not observed in
cells with low SPHK1 expression, it is less likely that this band is
non-speciﬁc. Further analysis using the antibody from Cell Signaling in
addition to our antibody detected similar two bands. siRNA for Sphk1
and Sphk1 cDNA overexpression experiments strongly suggest that
this lowmolecular band is derived frommouse SPHK1 (Supplementary
Fig. 1). SPHK1 is evolutionally highly conserved andmouse Sphk1 cDNAand human SPHK1 cDNA exhibit a high homology. Five important con-
served domains (C1–C5) are also observed in mouse Sphk1 cDNA.
Among these ﬁve domains, C1–C3 are thought to be catalytic domain,
and are located at the N-terminal part [43].
Although we were unable to completely separate 43 kDa and
28 kDa molecules by HPLC, (Supplementary Fig. 2b), it was revealed
that the proﬁle of SPHK1 enzyme activity paralleled that of 43 kDa
content but not that of 28 kDa. Interestingly, the heterogeneous
SPHK1 proteins has been reported in human platelets [44] and it has
also been reported that endogenous cathepsin B digests human
SPHK1 producing several smaller fragments including 30–31 kDa
and that its major cleavage site is located at H122 [45,46]. Our ob-
served 28 kDa form of mouse SPHK1 is very close to the molecular
size of 31 kDa molecule and the cleavage site by cathepsin B is also
conserved in mouse SPHK1.
This 28 kDa molecule was recognized by our antibody prepared
with the C-terminal 18 peptides immunization, suggesting that the
28 kDa molecule possesses the C-terminal sided-portion. Concerning
the relationship between molecular structure and enzyme activity, it
has been reported that deletion of only 69 amino acids from the wild
type human SPHK1 severely reduced its enzyme activity [47]. More-
over, it has also been reported that deletion of various regions from
SPHK1 mostly causes enzyme inactivation [48]. Thus, it is likely that
28 kDamoleculewas cleaved from43 kDa SPHK1 probably by cathep-
sin B or other proteases and that derived 28 kDa lacks SPHK1 enzyme
activity. The combination experiment of 43 kDa- and 28 kDa-rich
fractions did not indicate a dominant negative effect of 28 kDa mole-
cule (Supplementary Fig. 2c).
Human and rat SPHK1 promoter analyses have been reported
[33,49,50], and it was shown that Ap-2 and Sp1 sites within−0.2 kb
of the 5′ SPHK1 promoter are important for both endogenous and
NGF- or GDNF-induced transcription. However, mouse Sphk1 5′-pro-
moter has not been examined in detail [31]. Our present analysis dem-
onstrated that the short region between−53 bp and the ﬁrst exon is
important for mouse endogenous Sphk1 transcription of Friend cells
(Fig. 1). Interestingly, this region contains two putative Ets binding
domain and several MYB binding domains. FLI-1 and PU.1 belong
to the Ets transcription factor family. Within this region (between
−53 bp and −4 bp from the ﬁrst exon), Area II MYB-binding site
was found to be the most potent. Thus, Sphk1 transcription of Friend
cells is coordinately regulated by these proto-oncogenes/transcription
factors.
Considering our present data and previous reports together, min-
imal promoters involved in Sphk1 transcription in various cancer and
leukemia cells are not homogenous, and different cellular contexts or
signaling pathways determine how Sphk1 promoter region is stimu-
lated in its transcription. EMSA using this region as the labeled
probe revealed that c-MYB could bind this 5′-Sphk1 promoter region
and that band 3 is due to c-MYB protein binding (Fig. 2 b, c, and d).
This band decreased in HMBA-treated Friend cells (Fig. 2e), sug-
gesting the important role of MYB-induced SPHK1 in the HMBA sen-
sitivity of Friend cells.
Increased intensity of band 1 after HMBA treatment was unex-
pected and interesting. Conceivably, some proteins in Friend cells
bound with this region in competition with c-MYB, or independently
to suppress Sphk1 transcription. Unidentiﬁed transcription factors
and accessory factors induced by HMBA are such candidates. Further
analysis is needed to identify all the components involved in de-
creased Sphk1 transcription during HMBA-induced differentiation.
At the moment, complex occupancy of the 5′-promoter of Sphk1 by
heterogeneous factors during HMBA-induced differentiation revealed
that HMBA-induced modulation of Sphk1 transcription was more
complex than expected.
ChIP assay conﬁrmed the direct binding of c-MYB protein in vivo
(Fig. 3b). Moreover, siRNA against c-Myb and overexpression of
c-MYB conﬁrmed our results described above, suggesting c-MYB as
Fig. 7. Effects of SPHK inhibitor and S1P receptor antagonist. (a) SPHK1 overexpressed sc2 Friend cells were cultured in triplicate with or without 5 mM of HMBA in combination of
pertussis toxin (100 ng/ml), and VPC23019 (10 nM), and CAY10444 (10 nM). Cell proliferation (left) and the percentage of hemoglobin positive cells (right) on day 3 after HMBA
treatment were counted. (b) and (c) Similarly, effects of SPHK inhibitor and siRNA for Sphk1 were examined by counting cell proliferation and the percentage of
hemoglobin-positive cells of SPHK1 overexpresssed sc2. Effect of Sphk1 siRNA was shown in the Western blotting (7c left). In order to exhibit its inhibitory effect on two SPHK1
molecules, short exposure time was chosen to evaluate 28 kDa protein. Hemoglobin-positive cells were counted on day 2 after HMBA treatment. The mean±SD was shown and
the statistical signiﬁcance was examined. The asterisk denotes statistically signiﬁcant difference, pb0.001, between control and respective treated cells.
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cellular S1P and SPHK1 overexpression in c-MYB-overexpressed cells
are consistent.
Transcription factors and oncoproteins involved in Friend cell leu-
kemogenesis, c-MYB, PU.1, and FLI-1, exhibited a sequential decrease
by HMBA (Fig. 4a). These three molecules might function in concert
in both leukemogenesis and the differentiation process. However,
we focused on c-MYB based on the promoter analysis (Fig. 1) and
the fact that c-MYB is located upstream of SPHK1 (Fig. 2c and d). Dur-
ing HMBA-induced differentiation of Friend cells, SPHK1 but not
SPHK2 decreased very rapidly (Fig. 4a), suggesting a major role of
SPHK1 in determining the differentiation sensitivity of Friend cells.
It is of note that fully-committed Friend cells did not restore SPHK1
expression as well as cell proliferation even after removal of HMBA(Fig. 4b), suggesting the positive link between SPHK1 level and the
terminal erythroid differentiation of Friend cells.
Cellular S1P level was consistent with the rapid change of SPHK1
enzyme activity and protein levels. Okazaki et al. reported increased
ceramide level in Vitamin D3-induced HL-60 cells differentiation
[51]. However, the analysis of SPKH1/S1P signaling in the differentia-
tion process has not been extensively studied, and most studies
focused on the oncogenic (cell proliferation promoting) activity of
SPHK1 [21,52,53]. Considering the sphingolipid biostat model, it is
suggested that the increase of ceramide/S1P ratio due to the remark-
able decrease of S1P plays a signiﬁcant role in the cell cycle arrest of
differentiated Friend cells.
Friend cells exhibited rapid SPHK1 decrease during the HMBA-
induced differentiation. Thus, we examined the effects of stable
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ment. Our results of stably SPHK1 wild-type (WT) overexpressing
Friend cells are consistent with the concept that SPHK1 overexpression
enhances cell survival under cellular stress, and stimulates cell prolifer-
ation (Fig. 5b). The increase in cellular S1P of SPHK1 overexpressed cells
supports this idea. However, differentiation of these cells was delayed
signiﬁcantly but not completely suppressed. Actually some decrease in
cellular S1P was observed in SPHK1-overexpressed cells after HMBA-
treatment (Supplementary Fig. 4b). Cellular PU.1, FLI-I, and c-MYB of
SPHK1-overexpresssed cells treated with HMBA also exhibited the
similar rapid decrease (Supplementary Fig. 4a), suggesting that SPHK1
does not affect upstream transcription factors whose modulation is
the step necessary for the differentiation induction and that SPHK1
might not be the major regulator of the differentiation machinery in
Friend cells.
The c-MYB/SPHK1 axis supported the increased cellular S1P, en-
hanced cell proliferation and delayed differentiation induction of
c-MYB-overexpressed cells (Fig. 6). The signiﬁcance of SPHK2 in
Friend cells is of secondary importance, because cellular S1P rapidly
decreased regardless of non-ﬂuctuating SPHK2 levels (Fig. 4). Thus,
we did not discuss the role of SPHK2 in Friend cells further.
The involvement of cell surface S1P receptor in Friend cell prolifer-
ation was not signiﬁcant according to the results using S1P receptor
antagonists and pertussis toxin (Fig. 7a). The intracellular role for
SPHK1 has been reported in intestinal adenoma cell proliferation
[52]. SPHK inhibitor inhibited cell proliferation of Friend cells in a
dose-dependent manner (Fig. 7b) and interestingly, enhanced ery-
throid differentiation. It means that cell cycle arrest and/or SPHK1 in-
hibition enhanced HMBA-induced differentiation. However, because
SPHK1 inhibitor used is not free from other inhibitory effects against
other signaling molecules, we tried siRNA of Sphk1 (Fig. 7c). Although
siRNA of Sphk1 exhibited the incomplete and short duration of SPHK1
inhibition under our experimental condition, a mild and signiﬁ-
cant suppression of cell proliferation and enhanced differentiation
were observed compared with control siRNA at least in the early peri-
od of differentiation induction. Thus, although we did not explain
completely that high SPHK1 expression is inhibitory to HMBA-
induced differentiation because of its cell proliferation promoting ac-
tivity, our ﬁndings are strongly suggestive.
Taken together, our study revealed that the complex regulatory
mechanism is operated in the HMBA-induced erythroid differentiation
of Friend cells. We found (1) in Friend cells, c-MYB plays a major role
in Sphk1 transcription, (2) HMBA suppresses SPHK1 expression through
the reduced c-MYB expression, and (3) SPHK1 level affects the
HMBA-induced erythroid differentiation of Friend cells. Considering
the potent growth-suppressive effect of sphingosine kinase inhibitor
(Fig. 7) as well as the rapid decrease of SPHK1 of Friend cells during
HMBA-induced differentiation, our results strongly supports the ratio-
nale behind the therapeutics combining SPHK inhibitor with appro-
priate chemotherapeutic drugs or chemical differentiation inducer
against leukemia cells which are chemotherapy-resistant.
Supplementary data to this article can be found online at http://
dx.doi.org/10.1016/j.bbamcr.2013.01.001.
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